CompletedNCT02957123
Intranasal Autologous Macrophage Factors for Organic Brain Syndrome
About this title
Read the official source — NCT02957123Medication studyAges 18–80RussiaMental health
Understand this study
Who was this study for?
Listed age limits: 18 years to 80 years.
- Listed locations
- NovosibirskSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateStarted: March 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Russian Academy of Medical Sciences
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Russia
- Age range
- From 18 Years to 80 Years
- Official registry ID
- NCT02957123
- Official title
Show the full official title
Safety/Efficacy of Intranasally-Administered Bioactive Factors Produced by Autologous M2 Macrophages in Patients With Organic Brain Syndrome
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedNovosibirsk, Russia · Russia
Questions about this study
Who is behind this study?
The study sponsor is Russian Academy of Medical Sciences.
Did this study involve medication?
Yes. The study involved medication, including Intranasal auto-M2-BFs.
Who was this study for?
Listed age limits: 18 years to 80 years.
Want to explore more studies?
Explore studiesRelated studies
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Long-term nalmefene safety for alcohol dependence